Upadacitinib (Rinvoq)

AbbVie

Description

Janus kinase inhibitor

Indications

Moderate-to-severely active UC in adults

Contraindications

Absolute lymphocyte count less than 0.5x109 cells/litre; absolute neutrophil count less than 1x109 cells/litre; active serious infection including localised infection; active tuberculosis; haemoglobin less than 8g/dL. Caution in patients over 65 years; severe renal impairment; chronic or recurrent infection; diverticular disease; history of serious or opportunistic infection; known malignancy; patients at high risk for deep-vein thrombosis or pulmonary embolism; predisposition to infection; risk of viral reactivation; tuberculosis exposure. Patients should receive all recommended vaccinations before starting treatment (not live vaccines). Avoid during pregnancy and breastfeeding and in severe hepatic impairment. | Potential side effects: Abdominal pain; anaemia; cough; dyslipidaemia; fatigue; fever; headache; increased risk of infection; nausea; low white blood cell count; skin reactions; weight increase

Preparations Available

Oral tablet (modified release)

Quantity

Dose: 45mg once daily for 8 weeks, extended for a further 8 weeks if no response; maintenance 15–30mg once daily

Sizes Available

15mg modified-release tablets (28), £805.56; 30mg modified-release tablets (28), £1281.54; 45mg modified-release tablets (28), £2087.10

Price

15mg modified-release tablets (28), £805.56; 30mg modified-release tablets (28), £1281.54; 45mg modified-release tablets (28), £2087.10

More on: Janus kinase inhibitors